Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition - PubMed (original) (raw)

. 2008 Mar;31(3):599-610.

doi: 10.1183/09031936.00002007. Epub 2007 Nov 21.

Y-J Lai, R Dumitrascu, S S Pullamsetti, R Savai, H A Ghofrani, N Weissmann, C Schudt, D Flockerzi, W Seeger, F Grimminger, R T Schermuly

Affiliations

Free article

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition

E Dony et al. Eur Respir J. 2008 Mar.

Free article

Abstract

Phosphodiesterase (PDE) inhibitors are currently under investigation for the therapy of pulmonary hypertension. The present study was designed to investigate chronic effects of oral pumafentrine, a mixed selective PDE-3/4 inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension in rats. Treatment with pumafentrine (10 mg.kg(-1) daily) from week 4 to 6 after a single injection of MCT (60 mg.kg(-1)) partially reversed pulmonary hypertension and right heart hypertrophy in rats. In addition, small pulmonary arterial muscularisation, media hypertrophy and decrease in lumen area were largely reversed. Inhibition of smooth muscle proliferation under pumafentrine was demonstrated in vivo as was a pro-apoptotic effect of pumafentrine on vascular cells. Moreover, pumafentrine dose-dependently increased cyclic adenosine monophosphate levels and inhibited proliferation of cultured pulmonary arterial smooth muscle cells. In conclusion, oral pumafentrine partially reverses monocrotaline-induced pulmonary hypertension, lung vascular remodelling and right heart hypertrophy in rats.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources